Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 1:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Levodopa (L-dopa) Clear all
Completed No phase listed Observational

Influence of Theta Burst Stimulation and Carbidopa-Levodopa on Motor Performance in Stroke Patients

NCT00366184
View directory record Official record
Conditions
Stroke
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 29, 2026, 1:26 AM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Study of Carbidopa-levodopa

NCT03023059
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Carbidopa-Levodopa, 25 Mg-100 Mg Oral Tablet
Drug
Lead sponsor
Snyder, Robert W., M.D., Ph.D., P.C.
Individual
Eligibility
50 Years to 85 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Sep 29, 2026, 1:26 AM EDT
Terminated Phase 4 Interventional Results available

Levodopa and Exercise for Older Adults With Depression and Psychomotor Slowing

NCT04650217
View directory record Official record
Conditions
Depressive Disorder
Interventions
Carbidopa/levodopa, Placebo, Exercise training, Control
Drug · Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
60 Years to 100 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Sep 29, 2026, 1:26 AM EDT
Recruiting Phase 1 Interventional

Diagnosis of Pheochromocytoma

NCT00004847
View directory record Official record
Conditions
Pheochromocytoma, Endocrine Disease, Endocrine Diseases
Interventions
([18F]-DOPA), ([18F]-6F-DA)
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
3 Years to 120 Years
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2048
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 29, 2026, 1:26 AM EDT
Recruiting Phase 4 Interventional

Dopaminergic Therapy for Anhedonia - 2

NCT06075771
View directory record Official record
Conditions
Anhedonia, Depression
Interventions
Carbidopa Levodopa, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
25 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Sep 29, 2026, 1:26 AM EDT
Not listed Phase 1Phase 2 Interventional

A Study of IBRF Disorders of Consciousness Advanced Care/MultiModal Care Protocol in Severe Disorders of Consciousness

NCT02696512
View directory record Official record
Conditions
Brain Injury
Interventions
Polypharmacy using FDA-approved products, Median Nerve Stimulation (MNS), Nutraceutical Supplementation, Standard of Care
Drug · Device · Dietary Supplement + 1 more
Lead sponsor
International Brain Research Foundation
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Edison, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 1, 2016 · Synced Sep 29, 2026, 1:26 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease

NCT01474421
View directory record Official record
Conditions
Dyskinesias, Drug-induced
Interventions
AQW051, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
30 Years to 85 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Sacramento, California • Manhasset, New York • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Sep 29, 2026, 1:26 AM EDT
Not listed Phase 2 Interventional

Effect of L-Dihydoxyphenylserine on Locomotion, Postural Stability, and Fall Risk Reduction in Parkinson Disease

NCT02812147
View directory record Official record
Conditions
Parkinson Disease
Interventions
L-DOPS, Placebo
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
30 Years to 83 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Sep 29, 2026, 1:26 AM EDT
Completed Phase 2 Interventional

EMD 128130 for the Treatment of Parkinson's Disease

NCT00009048
View directory record Official record
Conditions
Parkinson's Disease
Interventions
EMD 128130, IV Levodopa
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 29, 2026, 1:26 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole

NCT03250117
View directory record Official record
Conditions
Parkinson Disease
Interventions
Ropinirole oral product, Ropinirole Implant
Drug
Lead sponsor
Titan Pharmaceuticals
Industry
Eligibility
30 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Orlando, Florida • Farmington Hills, Michigan • Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated May 5, 2023 · Synced Sep 29, 2026, 1:26 AM EDT
Terminated Phase 4 Interventional Results available

L-DOPA vs. Placebo for Depression and Psychomotor Slowing in Older Adults

NCT03761030
View directory record Official record
Conditions
Major Depressive Disorder, Dysthymia, Depression
Interventions
L-DOPA, Placebo Oral Tablet
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
60 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2023 · Synced Sep 29, 2026, 1:26 AM EDT
Not yet recruiting Phase 1 Interventional

AAV2-hAADC for Parkinson's Disease (PDCS-01)

NCT07267065
View directory record Official record
Conditions
Parkinson's Disease (PD), Early Onset Parkinson Disease
Interventions
AAV2-hAADC
Drug
Lead sponsor
Krzysztof Bankiewicz
Other
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 29, 2026, 1:26 AM EDT
Completed Phase 2Phase 3 Interventional

Safety and Efficacy Study of SYN115 in Parkinson's Patients Using Levodopa to Treat End of Dose Wearing Off

NCT01283594
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Tozadenant (SYN115) 60 mg BID, Placebo, Levodopa (L-dopa), Tozadenant (SYN115) 120 mg BID, Tozadenant (SYN115) 180 mg BID, Tozadenant (SYN115) 240 mg BID
Drug
Lead sponsor
Biotie Therapies Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
40
States / cities
Birmingham, Alabama • La Jolla, California • Loma Linda, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Sep 29, 2026, 1:26 AM EDT
Recruiting Phase 2 Interventional

An Investigational Scan (18F-DOPA PET/CT) for Improving the Clinical Management of Brain Tumors

NCT06667726
View directory record Official record
Conditions
Malignant Brain Neoplasm
Interventions
Computed Tomography, Fluorodopa F 18, Positron Emission Tomography
Procedure · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 29, 2026, 1:26 AM EDT
Completed Phase 4 Interventional Results available

DTA (Dopaminergic Therapy for Anhedonia) Study

NCT04723147
View directory record Official record
Conditions
Depression, Anhedonia
Interventions
Carbidopa Levodopa, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
25 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 15, 2024 · Synced Sep 29, 2026, 1:26 AM EDT
Completed Phase 4 Interventional Results available

Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)

NCT01770145
View directory record Official record
Conditions
Parkinson's Disease, Motor Symptoms, Akinesia, Hypomobility, Delayed Levodopa Onset
Interventions
APOKYN, L-dopa, Trimethobenzamide
Drug
Lead sponsor
MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
12
States / cities
Los Angeles, California • Reseda, California • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Sep 29, 2026, 1:26 AM EDT
Completed Phase 1 Interventional

A Study of the Safety and Pharmacokinetics of Levodopa Following Administration of CVT 301 (Levodopa Inhalation Powder) in Adults With Asthma

NCT02633007
View directory record Official record
Conditions
Asthma
Interventions
CVT-301 (levodopa inhalation powder), Carbidopa, Placebo
Drug · Other
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
25 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Daytona Beach, Florida • North Dartmouth, Massachusetts • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2016 · Synced Sep 29, 2026, 1:26 AM EDT
Completed Not applicable Interventional

Deep Brain Stimulation to Treat Symptoms of Parkinson's Disease

NCT00552474
View directory record Official record
Conditions
Parkinson Disease, Movement Disorders
Interventions
Libra Deep Brain Stimulation System
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years to 80 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
15
States / cities
Loma Linda, California • Gainesville, Florida • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2019 · Synced Sep 29, 2026, 1:26 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

1/2-Dopaminergic Dysfunction in Late-Life Depression (The D3 Study)

NCT04493320
View directory record Official record
Conditions
Depression, Cognitive Impairment, Gait Impairment
Interventions
Carbidopa/levodopa, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
60 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2023 · Synced Sep 29, 2026, 1:26 AM EDT
Completed Phase 1 Interventional

Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease

NCT03065192
View directory record Official record
Conditions
Idiopathic Parkinson's Disease, Parkinson's Disease, Basal Ganglia Disease, Brain Diseases, Central Nervous System Diseases, Movement Disorders, Nervous System Diseases, Neurodegenerative Diseases, Parkinsonian Disorders
Interventions
VY-AADC01
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
40 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
4
States / cities
San Francisco, California • Atlanta, Georgia • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2022 · Synced Sep 29, 2026, 1:26 AM EDT
Completed Phase 4 Interventional Results available

A Study of L-DOPA for Depression and Slowing in Older Adults

NCT02744391
View directory record Official record
Conditions
Major Depressive Disorder, Dysthymia, Depression Not Otherwise Specified, Decreased Processing Speed, Decreased Gait Speed
Interventions
Levodopa
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
60 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Sep 29, 2026, 1:26 AM EDT
Completed No phase listed Observational

Observational, Long-term Extension Study for Participants of Prior VY-AADC01 Studies

NCT03733496
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Not listed
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
40 Years and older
Enrollment
14 participants
Timeline
2018 – 2023
U.S. locations
3
States / cities
San Francisco, California • Atlanta, Georgia • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Sep 29, 2026, 1:26 AM EDT
Completed Phase 4 Interventional Results available

Vigor and the LDR in Parkinson Disease

NCT04821830
View directory record Official record
Conditions
Parkinson Disease
Interventions
carbidopa/levodopa, as prescribed by treating physician
Drug
Lead sponsor
University of Michigan
Other
Eligibility
45 Years to 90 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Sep 29, 2026, 1:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

PET Imaging of the Dopaminergic and Serotonergic Systems in Treated HIV Positive Subjects

NCT03581305
View directory record Official record
Conditions
Depression, HIV Infections, HIV-Associated Cognitive Motor Complex
Interventions
18F-FDOPA, 11C-DASB
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Sep 29, 2026, 1:26 AM EDT